Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P34949: Variant p.Arg219Gln

Mannose-6-phosphate isomerase
Gene: MPI
Feedback?
Variant information Variant position: help 219 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glutamine (Q) at position 219 (R219Q, p.Arg219Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CDG1B. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 219 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 423 The length of the canonical sequence.
Location on the sequence: help SHLMKSEKKVVVEQLNLLVK R ISQQAAAGNNMEDIFGELLL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         SHLMKSEKKVVVEQLNLLVKRISQQAAAGNNME---DIFGELLL

Chimpanzee                    SHLMKSEKKVVVEQLNLLVKRISQQAAAGNNME---DIFGE

Mouse                         SHLMKSEKKVVVEQLNLLVKRISQQVFDGNNME---DIYGK

Rat                           SHLMKSEKKVVVEQLNLLVKRISQQISNGNSMD---DICGE

Bovine                        SHLMKSEKKVVVEQLNLLVKRISQQVAAGNNME---DICGE

Caenorhabditis elegans        SRIWRTPKEKLQIVVDKLARRIQGHENK--------TALDE

Slime mold                    TSLLKADGLLISNNLKELNNRLNEKREEER------DDLDR

Baker's yeast                 SRVMNASDDKIKIQARSLVERSKNSPSDFNK-----PDLPE

Fission yeast                 NELMHKDEKRIQEFTPQLVQLAKSDANNFGGTEYGGKAFSD
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 423 Mannose-6-phosphate isomerase
Alternative sequence 163 – 224 KVPEFQFLIGDEAATHLKQTMSHDSQAVASSLQSCFSHLMKSEKKVVVEQLNLLVKRISQQA -> T. In isoform 2.



Literature citations
Carbohydrate-deficient glycoprotein syndrome type Ib: phosphomannose isomerase deficiency and mannose therapy.
Niehues R.; Hasilik M.; Alton G.; Koerner C.; Schiebe-Sukumar M.; Koch H.G.; Zimmer K.-P.; Wu R.; Harms E.; Reiter K.; von Figura K.; Freeze H.H.; Harms H.K.; Marquardt T.;
J. Clin. Invest. 101:1414-1420(1998)
Cited for: VARIANT CDG1B GLN-219; FUNCTION; CATALYTIC ACTIVITY; Genetic and metabolic analysis of the first adult with congenital disorder of glycosylation type Ib: long-term outcome and effects of mannose supplementation.
Westphal V.; Kjaergaard S.; Davis J.A.; Peterson S.M.; Skovby F.; Freeze H.H.;
Mol. Genet. Metab. 73:77-85(2001)
Cited for: VARIANTS CDG1B THR-140 AND GLN-219;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.